Download by
Scanning QR Code
No Stock Yet
No Data
Trevi Therapeutics 2Q Loss $8.1M >TRVI
Trevi Therapeutics 2Q Loss $8.1M >TRVI
Trevi Therapeutics GAAP EPS of -$0.14 beats by $0.04
Trevi Therapeutics press release (NASDAQ:TRVI): Q2 GAAP EPS of -$0.14 beats by $0.04. Company had total cash, cash equivalents and marketable securities of $78.9 million.
Press Release: Trevi Therapeutics Announces -3-
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.
Earnings Scheduled For August 11, 2022
Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million. • Dingdong (Cayman) (NYSE:DDL) is likely
Trevi Therapeutics (TRVI) Set to Announce Earnings on Thursday
Trevi Therapeutics (NASDAQ:TRVI – Get Rating) will be releasing its earnings data after the market closes on Thursday, August 11th. Analysts expect Trevi Therapeutics to post earnings of ($0.21) per
WealthTrust Axiom LLC Increases Stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI)
WealthTrust Axiom LLC increased its holdings in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI – Get Rating) by 245.6% during the 1st quarter, according to the company in its most recent 13F filing
Traders News Source Senior Editor Mark Roberts Interviews Jennifer Good CEO of Trevi Therapeutics
NEW YORK, NY / ACCESSWIRE / July 14, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued
Tpg Gp A, Llc Sells 436,431 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) Stock
Trevi Therapeutics, Inc. (NASDAQ:TRVI – Get Rating) major shareholder Tpg Gp A, Llc sold 436,431 shares of the stock in a transaction that occurred on Friday, July 1st. The stock was sold at an avera
Insider Selling: Trevi Therapeutics, Inc. (NASDAQ:TRVI) Major Shareholder Sells $1,248,192.66 in Stock
Trevi Therapeutics, Inc. (NASDAQ:TRVI – Get Rating) major shareholder Tpg Gp A, Llc sold 436,431 shares of Trevi Therapeutics stock in a transaction on Friday, July 1st. The shares were sold at an av
Trevi Therapeutics (NASDAQ:TRVI) PT Raised to $12.00
Trevi Therapeutics (NASDAQ:TRVI – Get Rating) had its price target raised by Oppenheimer to $12.00 in a research report sent to investors on Monday, Stock Target Advisor reports. Several other broker
Loading...
No Stock Yet